Myosin Light Chain Kinase Expression Induced via Tumor Necrosis Factor Receptor 2 Signaling in the Epithelial Cells Regulates the Development of Colitis-Associated Carcinogenesis
It has been suggested that prolonged inflammatory bowel diseases (IBD) may lead to colitis-associated carcinogenesis (CAC). We previously observed that the NF-κB activation in colonic epithelial cells is associated with increased tumor necrosis factor receptor 2 (TNFR2) expression in CAC development. However, the mechanism by which epithelial NF-κB activation leading to CAC is still unclear. Myosin light chain kinase (MLCK) has been reported to be responsible for the epithelial permeability associated with TNF signaling. Therefore we focused on the role of MLCK expression via TNFR2 signaling on CAC development. Pro-tumorigenic cytokines such as IL-1β, IL-6 and MIP-2 production as well as INF-γ and TNF production at the lamina propria were increased in the setting of colitis, and further in tumor tissues in associations with up-regulated TNFR2 and MLCK expressions in the epithelial cells of a CAC model. The up-regulated MLCK expression was observed in TNF-stimulated colonic epithelial cells in a dose-dependent fashion in association with up-regulation of TNFR2. Silencing TNFR2, but not TNFR1, resulted in restoration of epithelial tight junction (TJ) associated with decreased MLCK expression. Antibody-mediated blockade of TNF signaling also resulted in restoration of TJ in association with suppressed MLCK expression, and interestingly, similar results were observed with suppressing TNFR2 and MLCK expressions by inhibiting MLCK in the epithelial cells. Silencing of MLCK also resulted in suppressed TNFR2, but not TNFR1, expression, suggesting that the restored TJ leads to reduced TNFR2 signaling. Such suppression of MLCK as well as blockade of TNFR2 signaling resulted in restored TJ, decreased pro-tumorigenic cytokines and reduced CAC development. These results suggest that MLCK may be a potential target for the prevention of IBD-associated tumor development.
References
[1]
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, et al. (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359: 1541–1549. doi: 10.1016/s0140-6736(02)08512-4
[2]
Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228–1233. doi: 10.1056/nejm199011013231802
[3]
Ekbom A, Helmick C, Zack M, Adami HO (1990) Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 336: 357–359. doi: 10.1016/0140-6736(90)91889-i
[4]
Ekbom A, Helmick CG, Zack M, Holmberg L, Adami HO (1992) Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 103: 954–960.
[5]
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285–296. doi: 10.1016/j.cell.2004.07.013
[6]
Onizawa M, Nagaishi T, Kanai T, Nagano K, Oshima S, et al. (2009) Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 296: G850–859. doi: 10.1152/ajpgi.00071.2008
[7]
Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, et al. (1993) Tumour-necrosis-factor antibody treatment in Crohn’s disease. Lancet 342: 173–174. doi: 10.1016/0140-6736(93)91375-v
[8]
Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF (1992) Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 102: 529–537.
[9]
Blair SA, Kane SV, Clayburgh DR, Turner JR (2006) Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest 86: 191–201. doi: 10.1038/labinvest.3700373
[10]
Ikebe M, Inagaki M, Kanamaru K, Hidaka H (1985) Phosphorylation of smooth muscle myosin light chain kinase by Ca2+-activated, phospholipid-dependent protein kinase. J Biol Chem 260: 4547–4550.
[11]
Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, et al. (2005) Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 166: 409–419. doi: 10.1016/s0002-9440(10)62264-x
[12]
Chen C, Wang P, Su Q, Wang S, Wang F (2012) Myosin light chain kinase mediates intestinal barrier disruption following burn injury. PLoS One 7: e34946. doi: 10.1371/journal.pone.0034946
[13]
Liu X, Xu J, Mei Q, Han L, Huang J (2013) Myosin light chain kinase inhibitor inhibits dextran sulfate sodium-induced colitis in mice. Dig Dis Sci 58: 107–114. doi: 10.1007/s10620-012-2304-3
[14]
Su L, Nalle SC, Shen L, Turner ES, Singh G, et al. (2013) TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 145: 407–415. doi: 10.1053/j.gastro.2013.04.011
[15]
Iwamoto T, Yamada K, Shimizu M, Totsuka M (2011) Establishment of intestinal epithelial cell lines from adult mouse small and large intestinal crypts. Biosci Biotechnol Biochem 75: 925–929. doi: 10.1271/bbb.100887
[16]
Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, et al. (2004) Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 114: 1098–1106. doi: 10.1172/jci21086
[17]
Lowe EL, Crother TR, Rabizadeh S, Hu B, Wang H, et al. (2010) Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One 5: e13027. doi: 10.1371/journal.pone.0013027
[18]
Brozovic S, Nagaishi T, Yoshida M, Betz S, Salas A, et al. (2004) CD1d function is regulated by microsomal triglyceride transfer protein. Nat Med 10: 535–539. doi: 10.1038/nm1043
[19]
Nagaishi T, Pao L, Lin SH, Iijima H, Kaser A, et al. (2006) SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity 25: 769–781. doi: 10.1016/j.immuni.2006.08.026
[20]
Ichinose S, Muneta T, Koga H, Segawa Y, Tagami M, et al. (2010) Morphological differences during in vitro chondrogenesis of bone marrow-, synovium-MSCs, and chondrocytes. Lab Invest 90: 210–221. doi: 10.1038/labinvest.2009.125
[21]
Driscoll KE, Hassenbein DG, Howard BW, Isfort RJ, Cody D, et al. (1995) Cloning, expression, and functional characterization of rat MIP-2: a neutrophil chemoattractant and epithelial cell mitogen. J Leukoc Biol 58: 359–364.
[22]
Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, et al. (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798–1801. doi: 10.1126/science.1281554
[23]
Lahm H, Petral-Malec D, Yilmaz-Ceyhan A, Fischer JR, Lorenzoni M, et al. (1992) Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1. Eur J Cancer 28A: 1894–1899. doi: 10.1016/0959-8049(92)90031-v
[24]
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867. doi: 10.1038/nature01322
[25]
Eckmann L, Jung HC, Schurer-Maly C, Panja A, Morzycka-Wroblewska E, et al. (1993) Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of interleukin 8. Gastroenterology 105: 1689–1697.
[26]
Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, et al. (2010) Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59: 227–235. doi: 10.1136/gut.2009.184176
[27]
Ohno Y, Lee J, Fusunyan RD, MacDermott RP, Sanderson IR (1997) Macrophage inflammatory protein-2: chromosomal regulation in rat small intestinal epithelial cells. Proc Natl Acad Sci U S A 94: 10279–10284. doi: 10.1073/pnas.94.19.10279
[28]
Prakash R, Bharathi Raja S, Devaraj H, Devaraj SN (2011) Up-regulation of MUC2 and IL-1beta expression in human colonic epithelial cells by Shigella and its interaction with mucins. PLoS One 6: e27046. doi: 10.1371/journal.pone.0027046
[29]
Wang F, Schwarz BT, Graham WV, Wang Y, Su L, et al. (2006) IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology 131: 1153–1163. doi: 10.1053/j.gastro.2006.08.022
[30]
Graham WV, Wang F, Clayburgh DR, Cheng JX, Yoon B, et al. (2006) Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events. Characterization of the human long myosin light chain kinase promoter. J Biol Chem 281: 26205–26215. doi: 10.1074/jbc.m602164200
[31]
Ye D, Ma TY (2008) Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-alpha-induced regulation of myosin light chain kinase gene activity. J Cell Mol Med 12: 1331–1346. doi: 10.1111/j.1582-4934.2008.00302.x
[32]
Ye D, Ma I, Ma TY (2006) Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 290: G496–504. doi: 10.1152/ajpgi.00318.2005
[33]
Fish SM, Proujansky R, Reenstra WW (1999) Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function. Gut 45: 191–198. doi: 10.1136/gut.45.2.191
[34]
Taylor CT, Dzus AL, Colgan SP (1998) Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor alpha. Gastroenterology 114: 657–668. doi: 10.1016/s0016-5085(98)70579-7
[35]
Brand S (2009) Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 58: 1152–1167. doi: 10.1136/gut.2008.163667
[36]
Yamaji O, Nagaishi T, Totsuka T, Onizawa M, Suzuki M, et al. (2012) The development of colitogenic CD4(+) T cells is regulated by IL-7 in collaboration with NK cell function in a murine model of colitis. J Immunol 188: 2524–2536. doi: 10.4049/jimmunol.1100371
[37]
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, et al. (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350: 876–885. doi: 10.1056/nejmoa030815
[38]
Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337: 1029–1035. doi: 10.1056/nejm199710093371502
[39]
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476. doi: 10.1056/nejmoa050516
[40]
Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, et al. (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118: 560–570. doi: 10.1172/jci32453
[41]
Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, et al. (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 94: 965–973. doi: 10.1111/j.1349-7006.2003.tb01386.x
[42]
Mizoguchi E, Hachiya Y, Kawada M, Nagatani K, Ogawa A, et al. (2008) TNF receptor type I-dependent activation of innate responses to reduce intestinal damage-associated mortality. Gastroenterology 134: 470–480. doi: 10.1053/j.gastro.2007.11.055
[43]
Mizoguchi E, Mizoguchi A, Takedatsu H, Cario E, de Jong YP, et al. (2002) Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 122: 134–144. doi: 10.1053/gast.2002.30347
[44]
Wang M, Bronte V, Chen PW, Gritz L, Panicali D, et al. (1995) Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 154: 4685–4692.
